Pharmaceutical Executive December 12, 2025
Key Takeaways
- TrumpRx lowers drug prices but doesn’t address diagnosis and care access barriers, limiting its impact on patient outcomes.
- Pharma must develop DTP programs integrating education, testing, and telehealth to bridge the gap between awareness and clinical action.
- DTP programs should ensure seamless patient experiences, preserve clinical independence, and offer flexible prescription routing.
- Investing in DTP pathways can enhance patient access, improve health outcomes, and capitalize on TrumpRx’s pricing transparency.
TrumpRx’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.
TrumpRx promises to lower the price of hundreds of medicines for roughly 140 million Americans covered by Medicare or...
Today's Sponsors
Today's Sponsor